- Innovative Partnership: Absci Corp. and Memorial Sloan Kettering Cancer Center partner to develop up to six cancer therapeutics using generative AI.
- AI-Driven Drug Discovery: Absci’s AI technology will design antibodies to target cancer cells, while MSK provides oncology expertise.
- First Non-Profit Collaboration: This partnership marks Absci’s first collaboration with a non-profit research institute, expanding their existing network with companies like AstraZeneca and Merck.
Impact
- Cancer Therapeutics: The collaboration could lead to the development of novel cancer treatments, offering new hope for patients.
- AI in Oncology: The partnership highlights the growing role of AI in drug discovery, potentially accelerating cancer research.
- Emerging Hub: The Pacific Northwest continues to rise as a hub for AI-driven life sciences, driven by collaborations like this one.
- Broader AI Applications: Success in this partnership could pave the way for further AI applications in other therapeutic areas.
- Pioneering Effort: As Absci’s first non-profit partnership, this collaboration could influence more such efforts in the industry.
Eksentricity 
Leave a comment